Eikonoklastes Therapeutics

0 followers


Eikonoklastes is advancing a new generation of tissue factor (TF) immunotherapies – therapeutics designed to target the cell surface receptor now known to be prevalent on key components of the tumor microenvironment.

Industries

Headquarters

Stage

Employees

Links

Org chart

Bruce Halpryn
Co-Founder & CEO

Bruce Halpryn

Collapse
Samuel Lee
Co-Founder & Chief Business Officer
Samuel Lee, MD, MBA
Co-Founder, President, and Chief Business Officer